PharmaCyte Biotech Inc
PMCB
NASDAQ
Biotechnology
$0.55
USD
0.00 (+0.18%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $5.90M
Volume 131.5K
About PharmaCyte Biotech Inc
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. The company is headquartered in Las Vegas, Nevada and currently employs 2 full-time employees. The company went IPO on 2003-09-11. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
CEO
Mr. Joshua Silverman
HQ
Las Vegas, NEVADA, US
Founded
2003
Employees
2
Key Metrics
3 metrics our research team weighs before forming a view on PMCB.
Based on Quantli research · SEC filings · as of Q4 2026
METRIC
VALUE
CHANGE
TREND (3Y)
ROE (TTM)
-56.2%
-115.3 pp
EPS Growth (TTM)
-632.9%
—
Free Cash Flow (TTM)
$-5.15M
—
Financial Snapshot
Revenue
$0
— YoY
Gross Margin
—
— YoY
Net Income
$-19.42M
-163.4%
YoY
Operating Cash Flow
$-5.15M
-73.0%
YoY
Key Statistics
Open
$0.56
Previous Close
$0.55
Day Range
$0.54 - $0.57
52 Week Range
$0.53 - $1.51
Volume
131.5K
Average Volume (10 Days)
160.0K
Dividend Yield
—
Valuation Measurement
Market Cap
$5.90M
P/E Ratio (TTM)
—
Price / Book
0.17
Financial Highlights
Return on Assets
-41.5%
Return on Equity
-56.2%
Revenue (TTM)
$0
Net Income (TTM)
$-19.42M
Diluted EPS (TTM)
-$4.53
Total Cash (MRQ)
$18.60M
Levered FCF (TTM)
$-5.15M
Turn research into action
Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.
Similar Stocks
ENSC
Ensysce Biosciences Inc
$0.4000
▲ +14.8%
GOVX
GeoVax Labs Inc
$0.7200
▲ +0.0%
ERNA
Ernexa Therapeutics Inc
$4.27
▼ -0.7%
LABT
Lakewood-Amedex Biotherapeutics Inc
$2.27
▼ -2.6%
BOLT
Bolt Biotherapeutics Inc
$3.35
▲ +4.4%
BRTX
BioRestorative Therapies Inc
$0.2300
▲ +2.6%
ACXP
Acurx Pharmaceuticals Inc
$1.40
▼ -5.7%
XBIO
Xenetic Biosciences Inc
$3.28
▼ -0.3%
CDIO
Cardio Diagnostics Holdings Inc
$2.04
▲ +1.5%
DRMA
Dermata Therapeutics Inc
$1.46
▼ -7.0%
Earnings Calendar
Next Earnings
Estimated Q1 Release
Sep 14